Clinical Trials
31 trialsViral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
Huashan Hospital
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
M.D. Anderson Cancer Center
RACSMEI
Institut Pasteur du Cambodge
VSTs
Children's Hospital Medical Center, Cincinnati
Third Party Viral Specific T-cells (VSTs)
Children's Hospital Medical Center, Cincinnati
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
TETRAVI
Baylor College of Medicine
TETRAVI Expanded Access Program
Baylor College of Medicine
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
TRACE
University Hospital Freiburg
Gamma Capture
University of Pittsburgh
ACES
Pediatric Transplantation & Cellular Therapy Consortium
CEDAR
University of Oxford
R-MVST Cells for Treatment of Viral Infections
Columbia University
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Henry Ford Health System
PTN_POPS
Duke University
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
AdUP
University of Birmingham
ACE
Medical College of Wisconsin
An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy
Seoul National University Bundang Hospital
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
Theragene
Seoul National University Hospital
NSCLC
Henry Ford Health System
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
Syneos Health
Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
Institut Català d'Oncologia
CHALLAH
Baylor College of Medicine
EAP CHALLAH
Baylor College of Medicine
VIRAGE
Baylor College of Medicine
Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor
Sun Yat-sen University